Reach the investors backing rounds like this
Backed by Swisscanto, Diabetes Venture Fund +4 more · verified emails and LinkedIn on Datapile
Swisscanto leads $25M growth round for Swiss medtech Piomic - Dealroom
Piomic, a Swiss medtech startup spun out of ETH Zurich, develops physical stimulation therapies for deep tissue regeneration. Their lead product, the COMS One Therapy System, is a portable, non-invasive device for treating non-healing wounds. This $25 million growth round will fund clinical trials, US market approval filing, and expansion into new applications.
Swisscanto leads $25M growth round for Swiss medtech Piomic Dealroom
| Sep 18, 2026 | Aseptuva | $2.4M | Seed | Switzerland |
| Sep 14, 2026 | Aware Health | $12.0M | Seed | Switzerland |
| Sep 01, 2026 | xorlab | $5.3M | Series A+ | Switzerland |
| Aug 31, 2026 | KOVE medical | $1.8M | Seed | Switzerland |
You just read who funded Piomic. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.